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Mitomycin-C Induces the Apoptosis of Human Tenon’s
Capsule Fibroblast by Activation of c-Jun N-Terminal
Kinase 1 and Caspase-3 Protease
Gong Je Seong,1,2 Channy Park,2,3 Chan Yoon Kim,1 Young Jae Hong,1 Hong-Seob So,3
Sang-Duck Kim,4 and Raekil Park3
PURPOSE. To investigate whether mitochondrial dysfunction
and mitogen-activated protein kinase family proteins are impli-
cated in apoptotic signaling of human Tenon’s capsule fibro-
blasts (HTCFs) by mitomycin-C.
METHODS. Apoptosis was determined by Hoechst nuclei stain-
ing, agarose gel electrophoresis, and flow cytometry in HTCFs
treated with 0.4 mg/mL mitomycin-C for 5 minutes. Enzymatic
digestion of florigenic biosubstrate assessed the catalytic activ-
ity of caspase proteases, including caspase-3, caspase-8, and
caspase-9. Phosphotransferase activity of c-Jun N-terminal ki-
nase (JNK) 1 was measured by in vitro immune complex kinase
assay using c-Jun1–79 protein as a substrate. Mitochondrial
membrane potential transition (MPT) was measured by flow
cytometric analysis of JC-1 staining.
RESULTS. Mitomycin-C (0.4 mg/mL) induced the apoptosis of
HTCFs, which was characterized as nucleic acid and genomic
DNA fragmentation, chromatin condensation, and sub-G0/G1
fraction of cell cycle increase. The catalytic activity of
caspase-3 and caspase-9 was significantly increased and was
accompanied by cytosolic release of cytochrome c and MPT in
response to mitomycin-C. Treatment with mitomycin-C re-
sulted in the increased expression of Fas, FasL, Bad, and phos-
phorylated p53 and a decreased level of phosphorylated AKT.
Treatment with mitomycin-C also increased the phosphotrans-
ferase activity and tyrosine phosphorylation of JNK1, whose
inhibitor significantly suppressed the cytotoxicity of mito-
mycin-C.
CONCLUSIONS. Mitomycin-C induced the apoptosis of HTCFs
through the activation of intrinsic and extrinsic caspase cas-
cades with mitochondrial dysfunction. It also activated Fas-
mediated apoptotic signaling of fibroblasts. Furthermore, the
activation of JNK1 played a major role in the cytotoxicity of
mitomycin-C. (Invest Ophthalmol Vis Sci. 2005;46:3545–3552)
DOI:10.1167/iovs.04-1358
The most common reason for failure in glaucoma-filteringsurgery is scarring and fibrosis of the filtering bleb at the
level of the subconjunctival fibroblasts.1,2 Thus, the single
intraoperative application of anticancer chemotherapeutic
agents, including mitomycin-C and 5-fluorouracil (5-FU), is
widely used to increase the success of glaucoma-filtering
surgery by preventing fibroblast proliferation and excessive
scar formation.3–5 It has been suggested that antiproliferat-
ing effects of these agents are mediated by activation of the
apoptosis-signaling pathway in conjunctival fibroblasts.6
These drugs also induce the activation of apoptotic effector
molecules, including c-Jun N-terminal kinase (JNK) and
caspase-3, in human promyelocytic U937 cells. However,
the pivotal mechanism of antiproliferating and apoptotic
activity of mitomycin-C largely remains.
Recently, the effectiveness of mitomycin-C on the con-
junctiva has focused on aspects of antiproliferating and
apoptotic signaling for fibroblast functions, such as attach-
ment and proliferation. Specifically, mitomycin-C is known
to have a profound cytotoxic effect on cells in the mitosis
and proliferation phases of capillary and corneal endothelial
cells, corneal epithelial cells, and fibroblasts of conjunctiva
and Tenon capsule.5 Previous evidence suggests that mito-
mycin-C damages DNA by cross-linking bases in the same or
adjacent strands of DNA and that it eventually triggers a
powerful stimulus for apoptosis, including p53 induction. In
addition, mitomycin-C induces the activation of NF-B in
human T-cell lines.7–9
Apoptosis is an active process that plays pivotal roles in
the normal physiologic turnover of cells and in various
pathologic processes. It is characterized by dramatic cellular
alteration, particularly membrane blebbing, cell shrinkage,
chromosome condensation, and DNA fragmentation.10 Apo-
ptosis can be triggered by a wide variety of cellular stresses,
including UV radiation, ionizing radiation, heat shock, oxi-
dative stress, and DNA-damaging agents.11 JNK1 is also ac-
tivated during apoptosis induced by UV light, heat shock,
and ligation of the Fas antigen.12 Activation of JNK is in-
volved by dual phosphorylation of a Thr-Pro-Tyr motif, and
it seems to contribute to the initiation of apoptosis. Further-
more, recent evidence suggests that activation of the cas-
cade of cysteine proteases of the caspase family may play a
pivotal role in the execution of apoptosis.13 Caspases cleave
a variety of substrates. including components of cellular
DNA repair mechanisms such as poly ADP (adenosine
diphosphate)–ribose polymerase (PARP), DNA-dependent
protein kinase (DNA-PK), actin, fordins, lamin, and IB,
respectively. To clarify the mechanism by which mitomy-
cin-C induces apoptosis, we examined the implications of
the apoptosis-signaling pathway, including intrinsic and
extrinsic caspase family proteases, mitochondrial dysfunc-
tion, p53, mitogen-activated protein (MAP) kinase family
proteins, and AKT, in human Tenon’s capsule fibroblasts
(HTCFs).
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METHODS
Cell Culture
A primary cell line of HTCFs was established from subconjunctival
Tenon capsule isolated from patients during pterygium surgery. All
patients gave their informed consent before surgery. This study was
approved by the Yonsei University College Medicine ethics committee
in accordance with the provisions of the Declaration of Helsinki.
HTCFs were cultured at 37°C with 5% CO2 in Dulbecco modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum (FBS),
penicillin G (100 IU/mL), streptomycin (100 g/mL), and L-glutamine
(2 mM). HTCFs in exponential growth phase were used between
passages 2 and 6 for all experiments.
Treatment of HTCFs with Mitomycin-C
An HTCF monolayer seeded in 24-well plates or 10-cm dishes overnight
was washed with phosphate-buffered saline (PBS; pH 7.4) and then
treated with a single application of 0.4 mg/mL mitomycin-C for 5
minutes. Control fibroblasts were treated with PBS for the same period.
After treatment, cells were washed three times with PBS and were
maintained in DMEM for subsequent experiments.
Cell Viability
Cell viability was measured by using 3-(4,5-dimethylthiaziazol-2-yl)2,5-
diphenyl tetrazolium bromide (MTT). HTCFs were cultured in tripli-
cate in 96-well plates and were treated with 0.4 mg/mL mitomycin-C.
HTCFs were maintained in DMEM for 72 hours and were further
incubated with 500 g/mL MTT for 4 hours. Cells that stained posi-
tively with MTT were considered viable cells and were expressed as a
percentage compared with control cells.
Hoechst Staining and DNA Laddering
HTCFs were plated in slide chambers and were treated with 0.4 mg/mL
mitomycin-C, as described. Cells were then fixed in 3.7% formaldehyde
in PBS at 37°C for 10 minutes and were washed with PBS. Cells were
stained with 10 g/mL bisbenzimide (Hoechst 33258) at 37°C for 30
minutes, washed three times in PBS, and examined by fluorescence
microscopy. The ladder pattern of DNA strand break was analyzed by
agarose gel electrophoresis. Genomic DNA was isolated with the Wiz-
ard Genomic DNA purification kit (Promega, Madison, WI). After
ethanol precipitation, 50 g DNA in each lane was subjected to
electrophoresis on 1.5% agarose at 50 V for 3 hours. DNA was then
visualized under UV transillumination by staining with ethidium bro-
mide.
Flow Cytometric Analysis of Apoptosis and
Mitochondrial Membrane Potential Transition
Flow cytometric analysis of apoptotic cell death was performed as
described.14 HTCFs (107 cells/group) treated with 0.4 mg/mL mitomy-
cin-C for 12 hours were harvested, washed with Hanks balanced salt
solution (HBSS), and stained with 50 g/mL propidium iodide in 0.1%
Nonidet P-40. After the unbound dye was washed out, cells were
subjected to flow cytometric analysis to estimate the sub-G0/G1 frac-
tion in cell cycle analysis. Data were collected and analyzed (Consort
3.0 program; Becton-Dickinson, Mountain View, CA). Mitochondria of
HTCFs were incubated with 5 g /mL JC-1 at 37°C for 30 minutes.
After incubation, cells were washed three times with PBS and sub-
jected to flow cytometric analysis.
Western Blotting
HTCFs were lysed in 50 mM Tris, pH 8.0, 5 mM EDTA, 150 mM NaCl,
0.5% Nonidet P-40, and 1 mM phenylmethylsulfonyl fluoride (PMSF).
Protein was normalized to 100 g/lane, resolved on 7.5% to 12.5%
polyacrylamide gels, and blotted onto nitrocellulose membrane. The
nitrocellulose membrane was incubated with blocking buffer (5% skim
milk in TBS-T containing 0.05% Tween-20, 0.14 N NaCl, and 25 mM
Tris-HCl, pH 7.4) for 1 hour and then was incubated with the primary
antibodies against PARP, cytochrome c, VDAC, Bcl-2, Bad, Fas, FasL,
tBid, phospho-p53, p53, phospho-JNK1, JNK1, phospho-AKT, and AKT
proteins (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C.
Horseradish peroxidase–labeled goat anti–rabbit immunoglobulin G
antibody (1:5000 diluted) was added to the membrane, which was
further incubated for 1 hour. Immunoreactive bands were visualized
with enhanced chemiluminescence reagents (ECL; Amersham Life Sci-
ence, Amersham, UK). For reprobing, the same membrane was
stripped with 0.1 M glycine (pH 2.5) at room temperature for 30
minutes and then incubated with the other primary antibody.
In Vitro Kinase Assay of JNK1
HTCFs were lysed in ice-cold lysis buffer containing 10 mM Tris, pH
7.6, 50 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% 2-mercaptoetha-
nol, 1% aprotinin, 50 mM NaF, 2 mM PMSF, 5 M phenylarsine oxide,
and 100 mM sodium orthovanadate. The supernatant was incubated
with 1 g polyclonal anti–JNK1 antibody (Santa Cruz Biotechnology)
for 1 hour and then was washed twice with PAN buffer containing 10
mM piperazine-N-N-bis[ethanesulfonic acid (PIPES) pH 7.0, 1% apro-
tinin, and 100 mM NaCl. After incubation, a 10% solution of formalin-
fixed Staphylococcus aureus was added to anti–JNK1 immune com-
plex. Enzymatic activity of JNK1 was assayed by incorporation of
[-32P]adenosine triphosphate (ATP) (2 Ci/sample) with 1 g gluta-
thione-S transferase (GST)–c-Jun NT1–79 protein in a kinase reaction
buffer containing 20 mM Tris, pH 7.5, 20 mM MgCl2, 2 mM dithiothre-
itol, and 20 M cold ATP at 30°C for 15 minutes. Phosphorylation
reaction was terminated by an equal amount of 2 Laemmli sample
buffer and was boiled for 5 minutes. The protein was separated on 10%
SDS-PAGE and transferred to nitrocellulose membrane. 32P-labeled
GST–c-Jun N terminus1–79 protein was detected by autoradiography
and quantified on an analyzer (PhosphorImager; Fuji Co., Tokyo, Ja-
pan). After autoradiographic exposure to x-ray film, the nitrocellulose
membrane was incubated with blocking buffer for 1 hour and then
probed for phospho-JNK1 and JNK1 proteins by Western blot analysis.
Caspase Activity Assay
To measure the catalytic activation of caspase family cysteine pro-
teases, including caspase-3, caspase-8, and caspase-9, whole lysate of
HTCFs was prepared in a lysis buffer (1% Triton X-100, 0.32 M sucrose,
5 mM EDTA, 1 mM PMSF, 1 g/mL leupeptin, 2 mM dithiothreitol
[DTT], 10 mM Tris/HCl, pH 8.0) on ice for 30 minutes and centrifuged
at 20,000g for 15 minutes. Equal amounts of total protein were quan-
tified with a bicinchoninic acid kit (Sigma, St Louis, MO) in each lysate.
Catalytic activity of caspase-3 from the cell lysate was measured by
proteolytic cleavage of 100 M 7-amino-4-methylcoumarin (AMC)-
DEVD motif-specific peptide (Calbiochem Co., San Diego, CA) for 1
hour as a florigenic substrate and AMC as standard in an assay buffer
(100 mM HEPES, 10% sucrose, 0.1% Chaps, pH 7.5, 1 mM PMSF, 1
g/mL aprotinin, 1 g/mL leupeptin, and 2 mM DTT) at 380-nm
excitation wavelength and 460-nm emission wavelength. Cleavage of
florigenic substrates (Calbiochem Co.), including 100 M Z-IETD-7-
amino-4-trifluoromethycomarin (AFC) for caspase-8 and 100 M Ac-
LEHD-7-amino-4-trifluoromethycoumarin (AFC) for caspase-9, was mea-
sured by spectrofluorometer (Jasco FR-777, Midland, Canada) at 405
nm and 505 nm in HTCF lysate.
Preparation of Cytosolic and
Mitochondrial Fractions
Preparation of cytosolic and mitochondrial fractions was performed as
described in a previous report,15 with some modifications. In brief,
HTCFs were harvested, washed with ice-cold PBS, and incubated with
500 L buffer A (250 mM sucrose, 20 mM HEPES, pH 7.5, 10 mM KCl,
1.5 mM MgCl2, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and
10 g/mL each of leupeptin, aprotinin, and pepstatin A) on ice for 30
minutes. Then cells were disrupted by 20 passages through a 26-gauge
needle. Disrupted cells were centrifuged at 750g for 10 minutes. The
supernatant was centrifuged at 10,000g for 25 minutes. After centrif-
ugation, the cytosolic fraction was frozen at 70°C. The pellet contain-
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ing mitochondria was washed with ice-cold buffer A and resuspended
with cell lysis buffer. This resuspended pellet was incubated on ice for
30 minutes and then centrifuged at 10,000g for 25 minutes, and the
supernatant was collected as a cytosolic fraction of HTCFs.
Statistical Analysis
All values are represented as means  SD of triplicate experiments.
P  0.05 was considered statistically significant.
RESULTS
Apoptotic Effect of Mitomycin-C on HTCFs
Exposing HTCFs to mitomycin-C led to time- and dose-
dependent increases in the number of dead cells, as assessed
by MTT assay (Fig. 1A). A single exposure to mitomycin-C
for 5 minutes at the clinical concentration (0.4 mg/mL) in
62% of cells died after 48 hours. Time-dependent kinetics of
cell viability on mitomycin-C demonstrated that short peri-
ods (24 hours) of exposure did not exert significant cyto-
toxicity, but exposure became significant after 36 hours in
HTCFs. Next, to determine the nature of the cytotoxicity of
mitomycin-C in HTCFs, the phenotypic characteristics of
apoptosis were examined. Cells were treated with 0.4
mg/mL mitomycin-C for 5 minutes, refreshed with new
medium, and maintained for 48 hours. Then cells were
stained with Hoechst dye and visualized under a fluores-
cence microscope (Fig. 1B). Nuclei of the control culture
were oval round shape with homogeneous intensity,
whereas those of cells treated with mitomycin-C were con-
densed, had fragmented shapes, and were irregular in stain-
ing homogeneity. To further verify the apoptotic character-
istics, cells were cultured up to 72 hours after treatment
with 0.4 mg/mL mitomycin-C for 5 minutes, and genomic
DNA from cultures was extracted for 1.5% agarose gel elec-
trophoresis (Fig. 1C). Consistent with the findings of the
MTT assay, ladder-pattern fragmentation of genomic DNA
appeared in a time-dependent fashion at 48 and 72 hours
after treatment of mitomycin-C. DNA fragmentation by mit-
omycin-C was further analyzed as the sub-G0/G1 fraction of
cell cycle analysis by flow cytometry in HTCFs stained with
propidium iodide (Fig. 1D). In contrast to the control cul-
ture, a single exposure of 0.4 mg/mL mitomycin-C for 5
minutes dose dependently increased the sub-G0/G1 fraction
of HTCFs. Collectively, these data indicated that mitomy-
cin-C treatment decreased HTCF viability by apoptosis.
Catalytic Activation of Caspase-3 in
Mitomycin-C–Treated HTCFs
To ascertain the signaling pathway in apoptosis of HTCFs, cells
were maintained in the presence of 0.4 mg/mL mitomycin-C
for 5 minutes, and lysate was used to measure the catalytic
activation of caspase-3 at various time periods (Fig. 2A). The
enzymatic activation of caspase-3 started after 12 hours and
attained its peak at 36 hours. It sustained that level for 48 hours
and then declined. To further confirm the activation of
caspase-3, the cleavage of PARP, an intracellular biosubstrate of
the enzyme, was measured by Western blot analysis (Fig. 2B).
Cleavage of PARP from 116 kDa to 85 kDa was clearly demon-
strated at 24 hours after a single application of 0.4 mg/mL
mitomycin-C for 5 minutes.
We next applied the pharmacologic inhibitors of caspase
family proteases to test whether inhibition of these pro-
teases might have affected the cytotoxic effect of mitomy-
cin-C on HTCFs (Fig. 2C). The effect of pharmacologic
inhibitors of caspase-3 and caspase-1, including DEVD-AMC
and YVAD-AMC tetrapeptide, on the cytotoxicity of mitomy-
cin-C was measured by MTT assay. Cells were pretreated
with inhibitors of caspase proteases, followed by the addi-
tion of 0.4 mg/mL mitomycin-C for 5 minutes, and were
further maintained for 48 hours. Pretreatment with the
caspase-3 inhibitor DEVD-AMC (30 M) kept 60% to 87%
(P  0.05) of the cells viable, whereas the caspase-1 inhib-
itor YVAD-AMC did not have any effect on the cytotoxicity
of mitomycin-C. We further confirmed the inhibitory effect
of the caspase-3 inhibitor on the apoptosis of HTCFs by
mitomycin-C in 1.5% agarose gel electrophoresis (Fig. 2D).
Consistent with the results of the MTT assay, caspase-3
inhibition clearly abolished the ladder-pattern fragmentation
of genomic DNA in mitomycin-C–treated HTCFs.
FIGURE 1. Apoptosis of HTCFs occurred by mitomycin-C (MTC) ap-
plication for 5 minutes. (A) Dose-dependent (left) and time-dependent
(right) effects of MTC on viability were determined by MTT assay at 48
hours with various doses or up to 72 hours at the 0.4-mg/mL concen-
tration. Data represent mean  SD of three independent experiments
(*P  0.05; **P  0.01). (B) Cell nuclei with Hoechst staining were
observed under a fluorescence microscope 48 hours after treatment
with 0.4 mg/mL mitomycin-C for 5 minutes. (C) Genomic DNA of
fibroblasts was separated on 1.5% agarose gel. (D) Cell cycle analysis
was performed by flow cytometry after staining of propidium iodide in
cells treated with mitomycin-C.
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Catalytic Activation of Caspase-9 with
Mitochondrial Dysfunction in
Mitomycin-C–Treated HTCFs
The enzymatic activation of caspase-3 could be initiated by
upstream protease, either caspase-9 with mitochondrial dys-
function or caspase-8 with stimulation of the death receptor
Fas/FasL system. To test whether the activation of caspase-3
resulted from activation of the intrinsic caspase cascade and
from mitochondrial dysfunction, HTCFs were treated with 0.4
mg/mL mitomycin-C for 5 minutes and maintained up to 72
hours, and then lysate was used to measure the catalytic activ-
ity of caspase-9, the cytosolic release of cytochrome c, and
mitochondrial membrane potential transition (MPT). The cat-
alytic activity of caspase-9 started to increase at 12 hours and
reached a maximum at 24 hours (6.7-fold) after the application
of mitomycin-C (Fig. 3A). After fractionation of the cell lysate
into mitochondrial and cytosolic parts, two fractions separately
were used to measure the expression of cytochrome c by
Western blot (Fig. 3B). Cytochrome c in cytosolic fraction was
markedly increased at 24 hours after mitomycin-C treatment
and was time dependently diminished in expression. Consis-
tently, the immunoreactive band of mitochondrial cytochrome
c at 24 hours was the weakest in intensity among other lanes.
The purity of the mitochondrial fraction was verified by West-
ern blot analysis with anti–VDAC antibody.
We next determined the MPT of HTCFs after 0.4 mg/mL the
application of mitomycin-C for 5 minutes. Extranuclear mito-
chondria in the control culture primarily emitted as orange,
whereas mitochondria with MPT diffusely located through
whole cells were detected as green particles on JC-1 staining.
FIGURE 3. Mitomycin-C induced the activation of caspase-9 with mi-
tochondrial dysfunction in HTCFs. (A) Catalytic activity of caspase-9
was measured by cleavage of the florigenic biosubstrate Ac-LEHD-7-
AFC tetrapeptide (100 M) (*P  0.05; **P  0.01). (B) Cytosolic
release of cytochrome c was measured by Western blot analysis in
cytosolic and mitochondrial fractions. Mitochondrial fraction was ver-
ified with anti-VDAC antibody. (C) Mitochondrial MPT was determined
by flow cytometric analysis with JC-1 staining. (D) Expression of Bcl-2
and Bad was determined by Western blot in cells treated with 0.4
mg/mL mitomycin-C for 5 minutes.
FIGURE 2. Application of mitomycin-C caused the activation of
caspase-3 in HTCFs. Cells were treated with 0.4 mg/mL mitomycin-C
for 5 minutes and were maintained in fresh medium for the indicated
periods. (A) Catalytic activation of caspase-3 was measured by cleavage
of the florigenic biosubstrate DEVD tetrapeptide (*P  0.05; **P 
0.01). (B) Cytosolic expression of PARP was determined by Western
blot analysis with polyclonal anti–PARP antibody in cells treated with
mitomycin-C. (C) Pharmacologic inhibitors of the caspase-3 inhibitor
DEVD-AMC (30 M) and the caspase-1 inhibitor YVAD-AMC (30 M)
were pretreated, and cell viability was measured by MTT assay (*P 
0.05). (D) Cells were pretreated with DEVD-AMC or YVAD-AMC and
added to 0.4 mg/mL mitomycin-C for 5 minutes, and then genomic
DNA was separated on 1.5% agarose gel.
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Flow cytometric analysis of MPT demonstrated that the green
signal (Fig. 3C, lower right quadrant) of control culture was
15% and changed to 28% at 24 hours, 35% at 48 hours, and 41%
at 72 hours, respectively, after treatment with mitomycin-C.
Furthermore, mitomycin-C treatment markedly decreased anti-
apoptogenic Bcl-2 expression, whereas it increased apopto-
genic Bad expression in a time-dependent fashion (Fig. 3D).
These data indicated that mitomycin-C induced mitochondrial
dysfunction, which eventually activated the intrinsic caspase
cascade, including caspase-9 and caspase-3, in the apoptosis
signaling of HTCFs.
Increase in Expression of Fas/FasL, Bid
Truncation, and p53 Phosphorylation
by Mitomycin-C
We further questioned whether the death receptor Fas/FasL
system was implicated in the apoptosis of HTCFs by mitomy-
cin-C. Cells were treated with 0.4 mg/mL mitomycin-C for 5
minutes and were lysed for Western blot analysis at the indi-
cated time periods. Treating cells with mitomycin-C markedly
induced the increase in the expression of Fas and FasL proteins
in a time-dependent fashion with different kinetics (Fig. 4A).
We also measured the catalytic activity of capase-8, a down-
stream target of Fas. However, the enzymatic activation of
caspase-8 was not detectable in cells treated with mitomycin-C
for 72 hours (data not shown). We were further interested in
the translocation of truncated Bid (tBid), from cytosol to mito-
chondria, which eventually resulted in mitochondrial dysfunc-
tion. Our results showed that treating mitomycin-C time de-
pendently decreased the expression of cytosolic tBid,
indicating that tBid translocated into the mitochondria (Fig.
4B). In addition, treating mitomycin-C resulted in an increase of
p53 phosphorylation at the serine 15 residue in a time-depen-
dent fashion, even though mitomycin-C did not affect the
accumulation or degradation of the protein (Fig. 4C).
Furthermore, we tested the functional role of Fas receptor
in mitomycin-C–mediated HTCF apoptosis at 48 hours (Fig.
4D). Cells were pretreated with the neutralizing anti-Fas anti-
body or with the antisense oligonucleotide of Fas. This was
followed by the addition of 0.04 mg/mL mitomycin-C for 5
minutes, and viability was measured by MTT assay. Results
showed that blocking Fas signaling with the neutralizing anti-
Fas antibody or with the antisense oligonucleotide of the Fas
gene significantly antagonized the cytotoxicity of mitomycin-C
(P  0.05).
Suppression of Mitomycin-C Cytotoxicity by
Pharmacologic Inhibition of JNK1
MAP kinase family proteins have been implicated in the prolif-
eration, differentiation, and death of cells.16 Therefore, we
pretreated HTCFs with specific inhibitors of MAP kinase family
proteins—including MEK, JNK, and p38—in the presence of
mitomycin-C for 5 minutes and maintained this for 48 hours.
Only the pharmacologic inhibition of JNK1 with SP600125
antagonized the cytotoxicity of mitomycin-C, by 20% (P 
0.05), whereas other inhibitors, including PD98059 for MEK
and SB203580 for p38, did not (Fig. 5A). To verify these results,
in vitro kinase assay and Western blot for JNK1 were per-
formed in HTCFs treated with 0.4 mg/mL mitomycin-C for 5
minutes. Mitomycin-C increased the phosphotransferase activ-
ity of JNK1 toward the c-Jun N-terminal protein and the ty-
rosine phosphorylation of JNK1 at 3 to 12 hours after treat-
FIGURE 4. Mitomycin-C induced the activation of the Fas/FasL system
and p53 in HTCFs. Cells were treated with 0.4 mg/mL mitomycin-C for
5 minutes and then were maintained in fresh medium for the indicated
periods. (A–C) Cellular expression of Fas, FasL, tBid, phosphorylated
p53, and p53 was determined by Western blot analysis. (D) Cells were
pretreated with neutralizing anti–Fas antibody or Fas anstisense oligo-
nucleotide, followed by the addition of 0.4 mg/mL mitomycin-C for 5
minutes. Then cell viability was measured by MTT assay.
FIGURE 5. Inhibition of JNK1 activation antagonized the cytotoxicity
of mitomycin-C in HTCFs. (A) Cell viability was measured by MTT assay
in fibroblasts pretreated with 100 M MEK inhibitor PD98059, 5 M
JNK inhibitor SP600125, and 25 M p38 inhibitor SB203580, followed
by the addition of mitomycin-C (MTC). (B) Phosphotransferase activity
of JNK1 was measured by in vitro immune complex kinase assay
(upper panel). Tyrosine phosphorylation of JNK1 was tested by West-
ern blot with anti–phospho-JNK1 antibody.
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ment. Equal amounts JNK1 protein were confirmed by
Western blot with polyclonal anti–JNK1 antibody (Fig. 5B).
Decrease in AKT Phosphorylation of HTCFs
by Mitomycin-C
We tested the phosphorylation of AKT, of which activation is
well documented in the process of cell proliferation.12,17 After
5-minute exposure of HTCFs to 0.4 mg/mL mitomycin-C, cells
were maintained in DMEM supplemented with 10% FBS and
100 nM EGF (Genzyme, Cambridge, MA) for 72 hours, and the
lysate was used for Western blot analysis of AKT and phosphor-
AKT (Fig. 6). Phosphorylation of AKT was observed in resting
cells but was time dependently decreased by the addition of
mitomycin-C at 48 and 72 hours. Western blot analysis for AKT
protein verified that equal amounts of the protein were sepa-
rated on 10% SDS-PAGE.
DISCUSSION
In this study, we provide mechanistic evidence that mitomy-
cin-C induces the apoptosis of HTCFs at clinically a relevant
dose of 0.4 mg/mL. Traditionally, mitomycin-C was widely
used as a chemotherapeutic agent for the treatment of many
types of cancer. Recently, the mechanism of mitomycin-C has
been intensely investigated on fibroblast functions, including
proliferation and migration, in relation to conjunctival wound
healing after trabeculectomy. Mitomycin-C suppresses the mi-
tosis and proliferation of ocular compartments, including cap-
illary, corneal endothelium and epithelium, conjunctival fibro-
blasts, and Tenon’s capsule fibroblasts, respectively.5,17,18
Occleston19 first suggested that mitomycin-C was cytotoxic
to Tenon’s capsular fibroblasts. Shields et al. 20 further demon-
strated, through histologic examination of mitomycin-C–
treated draining blebs, that rather than inhibiting their prolif-
eration, mitomycin-C induced the death of fibroblasts. Later,
the nature of mitomycin-C cytotoxicity was revealed as apo-
ptosis by Crowstone et al.21 and Kim et al.22 Recently, Kim et
al.22 showed a cotreatment effect of mitomycin-C with alcohol
on the apoptosis of cultured corneal fibroblasts.23 Consistent
with previous results, we here present the apoptogenic effects
of mitomycin-C on HTCFs. In our study, apoptotic features in
mitomycin-C–treated cells were apparent, demonstrating chro-
matin condensation with nuclear fragmentation, ladder-pattern
fragmentation of genomic DNA, and increased sub-G0/G1 frac-
tion of cell cycle analysis.
In apoptosis-signaling cascades, two different initiation ma-
chineries, including extrinsic death receptor–mediated signal-
ing and intrinsic caspase family cysteine protease–mediated
signaling, play major roles in a variety of cell types.24,25 We
reconfirmed that the effector caspase of mitochondrial down-
stream caspase-3 plays a critical role in death of HTCFs by
mitomycin-C. These results are consistent with previous find-
ings showing that preincubation of CPP32-like protease inhib-
itor (Z-VAD-FMK) caused a decrease in LDH activity in mito-
mycin-C–treated keratinocytes.6,22 Mitochondrial dysfunction
in apoptotic signaling of mitomycin-C has not been specifically
addressed, even though several studies have already proposed
that Tenon capsular fibroblast undergoes apoptosis by topical
application of anti–metabolite drugs, including 5-FU and mito-
mycin-C.6,26 We present the first evidence that mitomycin-C
treatment induces mitochondrial dysfunction with the activa-
tion of caspase-9 in HTCFs. Caspase-9 is one of the upstream
activators of caspase-3; thus, we measured the activity of the
enzyme in this experimental system. Mitomycin-C increases
the catalytic activity of caspase-9 in a time-dependent fashion.
However, we could not detect the time difference of activation
between caspase-3 and caspase-9. Furthermore, characteristic
markers of mitochondrial dysfunction, including cytosolic
translocation of cytochrome c, MPT, and changes in Bcl-2 and
Bad expression, were clearly observed in mitomycin-C–treated
HTCFs. On the contrary, our data showed a decrease in ex-
pression of Bcl-2 after mitomycin-C treatment, high dose (1
g/mL) mitomycin-C could transiently increase the expression
of Bcl-2, which rapidly fade out at 2 hours in human gastric
cancer.27
Cytosolic release of cytochrome c is essentially required in
forming apoptosome complex, containing procaspase-9,
Apaf-1 and ATP, which triggers the autolytic activation of
caspase-9.28 Also, MPT, revealed by JC-1 staining, could cause
the cytosolic release of cytochrome c from mitochondria in
mitomycin-C treated HTCFs. Furthermore, the changes in ex-
pression of mitochondrial associated proteins, including Bcl-2
and Bad, may contribute to mitochondrial dysfunction, includ-
ing MPT and cytosolic release of mitochondrial cytochrome c,
by mitomycin-C. Among the death receptors on the cellular
surface, investigation into the apoptotic mechanism of Fas
(CD95) has been interested in fibroblast.29,30 Earlier studies
demonstrated that CD95L was expressed in HTCFs as well as in
lens epithelial cells and it mediated the activation of caspase-3
and caspase-9 in apoptosis.13,29 Consistent with the idea of
Crowstone et al.,21 we found an increase in expression of Fas
and FasL proteins in relation to the concentrations of mitomy-
cin-C in HTCFs. However, the expression of FasL in resting
control cells was less obvious compared to the work of Hueber
et al.29 In our experimental model, Fas/FasL expression of cells
was inducible by the addition of mitomycin-C in a time- and
dose-dependent manner. Whereas both expression and apo-
ptosis activity of CD95L in NIH 3T3 did not require de novo
synthesis of RNA or proteins.29 Interestingly, treatment of
mitomycin-C could not result in induction of FasL and Fas
expression in human gastric adenocarcinoma cells.31 Consis-
tent with TUNEL-sensitive DNA breaks in the works of Hueber
at al, pretreatment of both neutralizing anti-Fas antibody and
antisense oligonucleotide of Fas revealed that mitomycin-C
could activate the Fas/FasL system to transduce signals for
apoptosis in HTCFs. The implication of Fas/FasL system in
mitomycin-C mediated apoptosis was further evidenced by the
decrease in expression of tBid after treatment of mitomycin-C
in this study.
The decrease in cytosolic expression of tBid might affect
both cytosolic release of mitochondrial cytochrome c and MPT
in Fig. 3. However, we could not present the apparent activa-
tion of caspase-8, a bridge between Fas and Bid, in cell free
assay system (data not shown). However, caspase-8 was acti-
vated on mitomycin-C in SNU-16 human gastric adenocarci-
noma cells.31 We also found that p53 was phosphorylated at
serine 15 residue, which may also contribute the digestion of
Bid protein, unless changes in the accumulation of p53 protein
are present. The phosphorylation of p53 is generally accepted
as a hall marker of apoptogenic responder in various cell types
against genotoxic agents.32
FIGURE 6. Application of mitomycin-C (MTC) caused the phosphory-
lation of AKT in HTCFs. Phosphorylation of AKT in cells maintained in
DMEM supplemented with 10% FBS and 100 nM EGF for 72 hours,
treated with 0.4 mg/mL MTC for 5 minutes, was measured by Western
blot with anti–phospho-AKT antibody. Anti–AKT immunoblot revealed
that the same amount of protein was loaded.
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MAP kinases play a critical role in proliferation, differentia-
tion and degeneration of cells.16 In studies of pharmacological
inhibition of MAP kinases, including MEK inhibitor PD98059,
JNK inhibitor SP600125, and p38 inhibitor SB203580, we dem-
onstrated that activation of JNK1 was required in apoptosis of
HTCFs by mitomycin-C. Interestingly, JNK1 activation oc-
curred at an early point in time around 1 to 12 hours after
treatment of mitomycin-C in HTCFs before cellular morpho-
logic changes of death, apparently showing after 24 hours.
Moreover, phosphorylation of AKT was markedly disappeared
by mitomycin-C in HTCFs maintained in DMEM supplemented
with 10% FBS and 100 nM EGF for 72 hours. However, PKC-
was transiently increased within 2 hours after a high dose (1
g/mL) mitomycin-C and subsequently disappeared in human
gastric cancer MKN-74 cells.31
The effectiveness of mitomycin-C on other conjunctival
scarring diseases, including ocular cicatricial pemphigoid and
Stevens-Johnson syndrome, mostly depends on its apoptotic
ability to induce apoptosis of fibroblasts. Earlier studies dem-
onstrated that effectiveness of mitomycin-C in intraoperative
application to improve the postoperative outcome in the sur-
gical treatment of cicatricial shrinkage of conjunctival fornices
and in subconjunctival inoculation to prevent progression of
subconjunctival cicatrization in patients with ocular cicatricial
pemphigoid.33,34 Conversely, Foster et al.35 showed that sub-
conjunctival mitomycin was not efficacious in controlling con-
junctival inflammation and scarring. They suggested that com-
bined immunoglobulin therapy with methotrexate was more
effective at treating ocular cicatricial pemphigoid. In addition,
we could not reach a definitive conclusion to suggest that
mitomycin resistance of fibroblasts usually occurred because of
the ability of cells to escape apoptosis. At least two major
compartments, including fibroblasts and inflammatory cells,
are part of the process of ocular scarring (e.g., autoimmune
scarring diseases, wound healing). Thus, the termination pro-
cess of tissue damage to form scar tissue is, in part, dependent
on the role of immune cells, including inflammatory response,
cytokines, and tissue growth factors, at the local site. Taken
together with those of previous reports, our results demon-
strate that the apoptosis of fibroblasts tends to be beneficial
only in limited conditions of ocular tissue scarring, including
intraoperative and postoperative topical application, subcon-
junctival application of ocular cicatricial pemphigoid, and sub-
conjunctival treatment before transplantation of corneal epi-
thelial stem cells, respectively.
In summary, our data represent that mitomycin-C simulta-
neously induces activation of the extrinsic apoptotic pathway,
the Fas/FasL system, and the intrinsic caspase cascades with
mitochondrial dysfunction in HTCF culture. Our data indicated
that the predominant apoptotic role of mitomycin-C in HTCFs
may be attributed to the activation of Fas/FasL-mediated signal-
ing. Two pieces of evidence support this. First, along with
increased Fas/FasL expression, blocking of Fas protein and
mRNA by neutralizing anti–Fas antibody or antisense of Fas
significantly inhibited the cytotoxicity of mitomycin-C, even
though we could not observed the catalytic activation of
caspase-8. Second, decreased cytosolic expression of truncated
Bid by mitomycin-C might have contributed to the disruption
of mitochondrial membrane potential, indicating that mito-
chondrial dysfunction occurred. Findings from Kim et al.22
showing that pharmacologic inhibition of caspase-8 signifi-
cantly decreased LDH activity in mitomycin-treated–HTCFs
support this hypothesis.
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